Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637 is registered in ClinicalTrials.gov with MoonLake Immunotherapeutics AG as lead sponsor.

NCT NCT07007637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07007637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
MoonLake Immunotherapeutics AG
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
June 27, 2025
Completion date
June 13, 2028
Enrollment
835 (estimated)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa